Integrative Medical Center for Liver Diseases, Beijing 302 Hospital, Beijing, PR China; College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, PR China.
Department of Clinical Pharmacy, The Second Affiliated Hospital, University of South China, Hengyang, PR China.
Biomed Pharmacother. 2018 Mar;99:325-333. doi: 10.1016/j.biopha.2018.01.071.
Studies have shown that satins and herbal products have potential to treat non-alcohol fatty liver disease (NAFLD) in clinic. However, no study has compared their effects, and their mechanisms remain unresolved. Here, we choose lovastatin and two herbal products including berberine and curcumin to compare their effects in treating NAFLD. NAFLD model was established by high fat food, and rats were administrated with lovastatin, berberine, curcumin, berberine + curcumin at the dosage of 100, 100, 100, 50 + 50 mg/kg bw, respectively. The body weight, visceral fat gain, histological inspection and serum parameters were studied to exam the curative effects. In addition, mediators including SREBP-1c, caveolin-1, pERK, NF-κB, TNF-α, and pJNK were studied. Results showed that berberine + curcumin group exhibited lower body and fat weigh compared with lovastatin group. Biochemical assays showed that LDL-c, ALT, AST, ALP, MDA, LSP level were lower in berberine + curcumin group compared with lovastatin group. Lower expression of SREBP-1c, pERK, TNF-α, and pJNK were also observed in berberine + curcumin group. We conclude that combination of curcumin and berberine exhibited better ameliorative effects in treating NAFLD than lovastatin, and this enhanced effect is associated with oxidative stress, hepatic inflammation and lipid metabolism.
研究表明,他汀类药物和草药产品具有治疗非酒精性脂肪性肝病(NAFLD)的潜力。然而,尚无研究比较它们的疗效,其作用机制仍未解决。在这里,我们选择洛伐他汀和两种草药产品,包括小檗碱和姜黄素,比较它们治疗 NAFLD 的效果。通过高脂肪食物建立 NAFLD 模型,大鼠分别给予洛伐他汀、小檗碱、姜黄素、小檗碱+姜黄素,剂量为 100、100、100、50+50mg/kg bw。研究体重、内脏脂肪增加、组织学检查和血清参数,以检查疗效。此外,还研究了包括 SREBP-1c、窖蛋白-1、pERK、NF-κB、TNF-α 和 pJNK 在内的介质。结果表明,小檗碱+姜黄素组的体重和脂肪重量低于洛伐他汀组。生化分析表明,小檗碱+姜黄素组的 LDL-c、ALT、AST、ALP、MDA、LSP 水平低于洛伐他汀组。小檗碱+姜黄素组的 SREBP-1c、pERK、TNF-α 和 pJNK 的表达也较低。我们得出结论,姜黄素和小檗碱的联合使用在治疗 NAFLD 方面比洛伐他汀具有更好的改善作用,这种增强的效果与氧化应激、肝炎症和脂质代谢有关。
Eur J Pharmacol. 2014-12-24
World J Gastroenterol. 2015-2-21
BMC Endocr Disord. 2017-2-28
Drug Des Devel Ther. 2025-4-28
Front Pharmacol. 2025-1-30
Front Endocrinol (Lausanne). 2024-12-20
ACS Pharmacol Transl Sci. 2024-1-9
Diabetes Obes Metab. 2022-11